Exclusive Summary

• Distinct clinical differentiation: As a second-generation antipsychotic, ziprasidone has a remarkably low risk of weight gain and metabolic adverse effects (lipids/glucose), offering irreplaceable clinical value for patients at risk of metabolic syndrome.
• Massive and stable global demand: Targeting over 60 million active patients globally suffering from schizophrenia and bipolar disorder, this chronic lifelong therapy guarantees stable and consistent recurring distribution volumes.
• Patent cliff advantages: With Pfizer's originator (Geodon) patents globally expired, there are zero intellectual property barriers, making it ideal for cost-effective Chinese generics to capture originator market share in emerging markets.
• Tender competitiveness of the starting dose: The 20mg strength is the universally guideline-recommended starting dose with high turnover; combined with Chinese supply chain cost advantages, it is highly competitive for winning national procurement tenders.